Search clinical trials for: OPB-111077

Total 818 results

Otsuka Pharmaceutical Development & Commercialization...

Completed

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

Solid Tumors

United States
Hospital Universitario 12 de Octubre
Apices Soluciones S.L.; Otsuka Pharmaceutical Co., Ltd.; Vivia Biotech

Completed

Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia

Acute Myeloid Leukemia

Spain
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Solid Tumor

Korea, Republic of
National University Hospital, Singapore
Otsuka Pharmaceutical Co., Ltd.

Unknown

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

NPC | Refractory Tumor

Singapore
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

Advanced Hepatocellular Carcinoma

Korea, Republic of
Otsuka Novel Products GmbH

Terminated

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

Breast Cancer | Ovarian Cancer | Prostate Cancer | Endometrial Cancer | Salivary Gland Cancer | Squamous Cell Carcinoma of the Cervix

United Kingdom
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
National University Hospital, Singapore
Otsuka Pharmaceutical Co., Ltd.; Shin Nippon Biomedical Laboratories, Ltd.

Terminated

OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy

Nasopharyngeal Carcinoma

Singapore
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
Otsuka Beijing Research Institute
Otsuka Pharmaceutical Co., Ltd.

Unknown

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Non-Hodgkin's Lymphoma(NHL) | Multiple Myeloma(MM)

Hong Kong
Otsuka Beijing Research Institute

Completed

Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors

Malignant Solid Tumour

Singapore
Korea Otsuka Pharmaceutical Co., Ltd.

Unknown

An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors

Solid Tumor

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

Advanced Cancer

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

STAT3 Inhibitor for Solid Tumors

Solid Tumor | Advanced Cancer

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Co., Ltd.

Terminated

Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes

Leukemia

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Otsuka America Pharmaceutical

Completed

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Hannah Choe, MD
National Cancer Institute (NCI); Plexxikon

Terminated

Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

Acute Graft Versus Host Disease | Steroid Refractory Graft Versus Host Disease

United States
Progen Pharmaceuticals

Completed

Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

Cancer

United States
Progen Pharmaceuticals

Completed

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Age Related Macular Degeneration

United States, Mexico, Russian Federation
University of California, San Francisco
National Cancer Institute (NCI); National Institutes of Health (NIH)

Not yet recruiting

IMProving Adherence to Colonoscopy Through Teams and Technology (IMPACTT)

Colorectal Cancer | Colon Cancer | Cancer Colorectal

United States
Mackay Memorial Hospital
OBI Pharma, Inc

Unknown

Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

Ovarian Cancer

Taiwan
Northern State Medical University

Completed

Normothermiс Cardiopulmonary Bypass Increases Cerebral Oxygenation During Valve Surgery

Heart Valve Diseases

Russian Federation
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (OPS-2071Ph1)

Healthy

Korea, Republic of
University of Pennsylvania

Completed

SupportBP 2.0:Behavioral Science and Enrollment in Remote Monitoring for Hypertension Management

Hypertension

United States
Johns Hopkins Bloomberg School of Public Health
Makerere University; Pontificia Universidad Javeriana; The Bloomberg Family Foundation...

Completed

Use of Consent Language and Mode to Improve Interactive Voice Response Survey in Colombia and Uganda

Noncommunicable Diseases | Surveys and Questionnaires

Colombia, Uganda
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
Eye & ENT Hospital of Fudan University

Recruiting

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Oropharynx Carcinoma

China
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects

Atopic Dermatitis

Japan
NYU Langone Health
National Institute on Drug Abuse (NIDA)

Completed

Clinical Reminder Changes to Increase Smoking Cessation Treatment in Outpatient Psychiatry

Smoking Cessation

United States
University of Pennsylvania

Completed

Opt-In Versus Opt-Out for Colorectal Cancer Screening Outreach

Cancer of the Colon
University of Pennsylvania
National Institute on Aging (NIA)

Completed

Hepatocellular Carcinoma Surveillance in Cirrhotics

Hepatocellular Carcinoma | Cirrhosis

United States
Otsuka Beijing Research Institute

Recruiting

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD

Atopic Dermatitis (AD)

China
Rigshospitalet, Denmark

Recruiting

Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens.

COVID-19 | Influenza | RSV Infection

Denmark
IlDong Pharmaceutical Co Ltd

Recruiting

IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Type 2 Diabetes

Germany
First Affiliated Hospital of Harbin Medical University

Completed

Efficiency and Changes of Cytokines Expression in Tear After Intense Pulsed Light Treating Dry Eye Disease

Dry Eye Syndromes

China
Otsuka Beijing Research Institute

Recruiting

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

China
Otsuka Beijing Research Institute

Recruiting

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

Atopic Dermatitis (AD)

China
Fudan University

Completed

Acute Health Effects of Ozone Exposure

Pulmonary Function

China
University of Oklahoma
National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes... and other collaborators

Completed

HIV Risk and Prevention in Women

HIV

United States, Russian Federation
University of Wisconsin, Madison
Progen Pharmaceuticals

Terminated

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Prostate Cancer

United States
International Centre for Diarrhoeal Disease Research...

Completed

Poliovirus Vaccine Trial in Bangladesh

Healthy Infants

Bangladesh
Otsuka Pharmaceutical Co., Ltd.

Completed

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Auburn University
University of Missouri-Columbia; University of Utah

Recruiting

Ketone Ester and Acute Salt (KEAS) in Young Adults (KEAS)

Hypertension | Salt; Excess

United States
Valo Health, Inc.

Withdrawn

Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) (RESTORE)

Myocardial Infarction
Ospedale San Raffaele

Unknown

Expiratory Flow Limitation and Mechanical Ventilation During Cardiopulmonary Bypass in Cardiac Surgery

Mitral Regurgitation | Aortic Regurgitation

Italy
Otsuka Pharmaceutical Co., Ltd.

Completed

Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
University of Pennsylvania

Completed

COVID-19 SAFE Enrollment (COVID SAFE)

Covid19

United States
University of Tromso
Norwegian Council for Mental Health; The Dam Foundation; Norwegian Directorate...

Active, not recruiting

Opp - a Universal Mental Health Promoting Mobile Application for Adolescents (Opp)

Mental Health Wellness 1

Norway
Assistance Publique Hopitaux De Marseille

Completed

Evaluation of Optical Pumping Magnetometer Sensors for MagnetoEncephaloGraphy Imaging (OPM)

Epilepsy

France

Search clinical trials for: OPB-111077

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations